US/UK/Canada

Share

Pick a time period -
Tags ( Active)

SLS Invest AB today entered into an agreement with Biolin Scientific regarding the sale of Sophion Bioscience

Stockholm, July 6, 2011. Today, SLS Invest AB signed an agreement with Biolin Scientific AB, a subsidiary of Ratos AB, concerning the sale of SLS Invest’s 19.3 percent shareholding in Sophion Bioscience A/S. All remaining shareholders in Sophion has agreed to sell their shares at the same time. The sales price is DKK 155 million in total of which DKK 10 million depend on sales in 2011/12. The sale is expected to be concluded in Q3 2011.Per Carendi, CEO of SLS Invest, comments:"The sale of Sophion to Biolin Scientific will ensure the further development of Sophion's technology within

SLS Invest to strengthen its Board of Directors

Stockholm, April 12, 2011. SLS Invest AB – one of Scandinavia’s leading investors focusing on Life Sciences – has elected Martin Nicklasson as new Member of the Board. Martin Nicklasson has vast experience from leading positions in several pharmaceutical companies. He was most recently CEO and President for Swedish Orphan Biovitrum (SOBI), a Swedish based pharmaceutical company.Lars Ingelmark, Chairman of the Board, SLS Invest:“SLS Invest’s portfolio has reached a point where a number of the companies have products on the market, or are in the position where they have initiated – or

Per Carendi new CEO of SLS Venture

The board of the Scandinavian venture capital group SLS Venture has appointed Per Carendi new chief executive officer. He has many years’ of experience from taking an active part in the work of the boards of several companies, lately focusing on the life science sector. Per is presently chairman of the board of SLS Venture’s portfolio company Doxa.”Many of SLS Venture’s portfolio companies are facing commercialisation, strategic acquistions, mergers or sales. Per has with great success taken part in and carried out commercialisations as well as strategic company transactions – most recently

SLS Venture invests in promising US oncology company

SLS Venture, a Scandinavian venture capital company, has co-invested in the US oncology company, Light Sciences Oncology, Inc., which is about to start a Phase III clinical trial of its promising liver cancer treatment.Light Sciences Onclogy, Inc., a privately held company based in Seattle, United States, is focused on the development and commercialization of the Light Infusion TechnologyTM (LitxTM) for the treatment of solid tumors. The financing round, totalling US$67 million of Series A Preferred shares, will enable Light Sciences Oncology, Inc. to further develop its rich clinical

SLS Venture sells its 23 per cent ownership in Carmel Pharma AB

SLS Venture, a Scandinavian venture capital company, has signed an agreement to sell its 23 per cent ownership in Carmel Pharma AB to 3i Group Plc. With SLS Venture as a key owner, Carmel Pharma AB has experienced a period of internationalisation and rapid growth. The largest market today is the United States, growing almost 40 per cent during the last year. “We will realise a good return on our investment and ownership efforts in Carmel Pharma AB. In line with our value creation and exit-focused business model, it is now time for us to exit”, Jonas Frick, CEO of SLS Venture, explains.

Karin Hehenberger new Senior Investment Director at SLS Venture

SLS Venture, a Scandinavian venture capital company, has appointed Karin Hehenberger Senior Investment Director. Her most recent assignment was at the NASDAQ-listed company Eytech Pharmaceuticals, where she worked as Senior Director of Scientific and External Affairs.”Several of SLS Venture’s portfolio companies are at the brink of being commercialised, something which means new challenges for the management groups of these companies”, said Jonas Frick, Chief Executive Officer of SLS Venture. ”It is crucial for the future success of SLS Venture to support the management and take part in

There are no items matching the current filter
There are no more items matching the current filter
Back to top